Shanghai, China, January 22 – The 5th Annual Lunjian Awards 2024, themed “XinSheng · LunJian,” guided by the China News of Drug Information Association and organized by the Sailing Health, recently unveiled its “Annual Star of Innovation.” Focusing on emerging products and forces within the healthcare industry, the list aims to collectively uphold the upward momentum in the face of uncertain market conditions.
Asieris has secured a spot on the list with its innovative bladder cancer diagnosis solution – Hexvix® combined with blue light cystoscopy. Hexvix® stands as the only domestically approved imaging agent used for diagnosing or operating on bladder cancer (including in situ carcinoma), filling a crucial gap in the domestic market. When combined with blue light cystoscopy, Hexvix® enhances detection rates by 43.3% compared to traditional white light cystoscopy, thereby reducing recurrence rates and effectively meeting unmet clinical needs.
As a globally specialized innovative pharmaceutical company, receiving the “Annual Star of Innovation” accolade affirms Asieris’ innovative strength in the specialty field. Asieris will continue to prioritize patient-centricity, deeply exploring their pain points and unmet clinical needs, advancing drug clinical development efforts, offering innovative solutions for patients, and enhancing the diagnostic and treatment standards for bladder cancer.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.